ARTICLES BY LOUIS

• No Prescription For Fake News

  1/22/2018

  We could never get away with “fake news” here. You’d run us out of town in a New York minute. But here’s some thoughts and historical perspective on this theme swirling around us today.

• Innovation Envy: Surfing California For Next Biopharma Wave

  1/16/2018

  If you’re interested in new tech and innovation – including outside of the biopharma space – and enjoy warm weather and coastlines, you won’t help but envy Ravi Kiron. Merck KGaA has given him the job of all jobs. Kiron has became the head of biopharma external innovation at Merck’s EMD Serono, Inc., and tasked with establishing its Silicon Valley Innovation Hub. Try not to be too jealous of Kiron as you’re reading. More jobs like his may be on the way. 

• Biopharma Experts Are Consistent: Expect More Cells, And Outsourcing

  1/5/2018

  When queried about the areas of most importance to them, their companies, and the biopharma outsourcing industry over the next 12 months, experienced professionals from around the world came back with this: cells, cells, and more cells.

• Thought Leadership Increases Sales

  12/1/2017

  According to new research from Edelman (the world’s largest PR firm) and LinkedIn – presented in a webinar I attended – expectations for thought leadership greatly undershoot their actual impacts on demand generation, RFP opportunities, new business opportunities, and increased sales.

• Pastries And Process: A Recipe for Innovation At CDMOs

  11/27/2017

  Hard truths offset by soft skills make up the outsourced drug development and manufacturing industry. Here are some of those truths, skills, and their syntheses for innovation at CDMOs, from some accomplished biopharma professionals.

• Bigger Pharma Supports Biotech Outsourcing

  11/14/2017

  Mersana Therapeutics has a powerful weapon in its battle to combat supply-chain complexity: A collaborative partnership with Takeda’s Millennium. We’ll look at how Takeda assists this biotech in the contract development and manufacturing of drug candidates. Today more than ever, biotechs rely on this type of Bigger Pharma assistance. 

• You Can Do Everything Right, But Still Get Burned By Outsourcing

  11/3/2017

  This is a narrative of how a virtual biotech did everything in its power to execute on an outsourcing strategy, but still suffered a critical setback at its service provider, told be Marilyn Bruno, CEO of Aequor, Inc. 

• Lessons From Mersana's Outsourced Model For ADCs

  10/24/2017

  Antibody-drug conjugates (ADCs) are on the move in the regulatory approval pipeline. Time again for us to view this technology through our prism of external support systems to see what we can further learn about our industry. Luckily, we get that view through the eyes of Michael Kaufman, Senior Vice President of CMC for Cambridge, Mass-based Mersana Therapeutics. 

• Outsourcing Dreams In Latin America

  10/4/2017

  When Boehringer Ingelheim swapped its consumer healthcare assets with Sanofi, Edgardo Rodriguez went along, too. It was like walking to the other side of the street in his beloved Buenos Aires. And his “new” job at Sanofi runs down the same road: Manage a supply chain for a European pharmaceutical company that includes dozens of CDMOs throughout Latin America. 

• Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing

  9/28/2017

  Jens Vogel, President & CEO, BI Fremont Inc., can’t help seeing two sides to most everything associated with the development and manufacturing of biologics. For example, he says we are in an era that at the same time can be dubbed “Death of the Blockbuster” and “Return of the Blockbuster.”